UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2023
RAFAEL HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | | 1-38411 | | 82-2296593 |
(State or other jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
520 Broad Street Newark, New Jersey | | 07102 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: 212 658-1450
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b)-2 of the Exchange Act:
| Title of each class | | Trading Symbol | | Name of each exchange on
which registered |
| Class B common stock, par value $0.01 per share | | RFL | | New York Stock Exchange |
Item 8.01 Other Events.
On August 1, 2023, Rafael Holdings, Inc. (the “Company”) purchased 4,000,000 shares of common stock (the “Shares”) of Cyclo Therapeutics, Inc., a Nevada corporation (“Cyclo”), and a warrant to purchase an additional 4,000,000 Shares (the “Warrant”), for an aggregate purchase price of $5,000,000. The Warrant has an exercise price of $1.25 per share, and the Warrant will be exercisable for a period of seven years.
As disclosed on the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 5, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Cyclo to purchase the Shares and the Warrant. The obligations of the Company and Cyclo to consummate the closing of the Purchase Agreement were subject to, in addition to other conditions, Cyclo obtaining the approval of its stockholders to the consummation of the transactions contemplated by the Purchase Agreement in accordance with Listing Rule 5635 of The Nasdaq Stock Market, Inc. Such stockholder approval was obtained on July 31, 2023.
The Shares and Warrants purchased on August 1, 2023 are in addition, to 2,514,970 shares of common stock of Cyclo and warrants to purchase an additional 2,514,970 shares of common stock of Cyclo (at an exercise price of $0.71 per share) the Company purchased in April 2023.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | RAFAEL HOLDINGS, INC. |
| | | |
| | By: | /s/ William Conkling |
| | | Name: William Conkling |
| | | Title: Chief Executive Officer |
Dated: August 2, 2023
2
